Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Physiotherapy as an immunoactive therapy? A pilot study.
Immunohistochemical detection of sphingosine-1-phosphate and sphingosine kinase-1 in human tissue samples.
Evaluation of the 2010 McDonald multiple sclerosis criteria in children with a clinically isolated syndrome.
Revisiting The Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures.
Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening.
JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene.
Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo.
Spatiotemporal distribution of white matter lesions in relapsing-remitting and secondary progressive multiple sclerosis.
The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis.
Ximino
Neuromyelitis optica with very late onset.
Behçet's Disease Presenting with Acute Transverse Myelitis: MRI Findings and Review of the Nosology. A Case Report.
Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS] (RECYCLINE)
Functional role of TRP channels in modulating ER stress and Autophagy.
Epidermal pigmentation in the human lineage is an adaptation to ultraviolet radiation.
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).
Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis-Report of Two Cases.
Interpretation and visualization of non-linear data fusion in kernel space: study on metabolomic characterization of progression of multiple sclerosis.
[Pharmacological properties and clinical efficacy of fingolimod hydrochloride (Imusera®/Gilenya®) for the treatment of multiple sclerosis].
Emerging tumefactive MS after switching therapy from interferon-beta to fingolimod: A case report.
Effects of Dalfampridine Extended-Release Tablets on 6-Minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-Blind, Placebo-Controlled Trial.
Impact of Cigarette Smoking on Conversion from Clinically Isolated Syndrome to Clinically Definite Multiple Sclerosis.
[Cannabinoid drugs for neurological diseases: what is behind?].
Novartis updates US label on Gilenya® following discussions with the FDA
Autoinflammatory grey matter lesions in humans: cortical encephalitis, clinical disorders, experimental models.

Pages